BACKGROUND: Viral infections are the most frequent cause of asthma exacerbations and are linked to increased airway reactivity (AR) and inflammation. Mice infected with respiratory syncytial virus (RSV) during ovalbumin (OVA)-induced allergic airway inflammation (OVA/RSV) had increased AR compared with OVA or RSV mice alone. Furthermore, interleukin 17A (IL-17A) was only increased in OVA/RSV mice. OBJECTIVE: To determine whether IL-17A increases AR and inflammation in the OVA/RSV model. METHODS: Wild-type (WT) BALB/c and IL-17A knockout (KO) mice underwent mock, RSV, OVA or OVA/RSV protocols. Lungs, bronchoalveolar lavage (BAL) fluid and/or mediastinal lymph nodes (MLNs) were harvested after infection. Cytokine expression was determined by ELISA in the lungs or BAL fluid. MLNs were restimulated with either OVA (323-229) peptide or RSV M2 (127-135) peptide and IL-17A protein expression was analysed. AR was determined by methacholine challenge. RESULTS: RSV increased IL-17A protein expression by OVA-specific T cells 6 days after infection. OVA/RSV mice had decreased interferon-β protein expression compared with RSV mice. OVA/RSV mice had increased IL-23p19 mRNA expression in lung homogenates compared with mock, OVA or RSV mice. Unexpectedly, IL-17A KO OVA/RSV mice had increased AR compared with WT OVA/RSV mice. Furthermore, IL-17A KO OVA/RSV mice had increased eosinophils, lymphocytes and IL-13 protein expression in BAL fluid compared with WT OVA/RSV mice. CONCLUSIONS: IL-17A negatively regulated AR and airway inflammation in OVA/RSV mice. This finding is important because IL-17A has been identified as a potential therapeutic target in asthma, and inhibiting IL-17A in the setting of virally-induced asthma exacerbations may have adverse consequences.
BACKGROUND:Viral infections are the most frequent cause of asthma exacerbations and are linked to increased airway reactivity (AR) and inflammation. Mice infected with respiratory syncytial virus (RSV) during ovalbumin (OVA)-induced allergic airway inflammation (OVA/RSV) had increased AR compared with OVA or RSVmice alone. Furthermore, interleukin 17A (IL-17A) was only increased in OVA/RSVmice. OBJECTIVE: To determine whether IL-17A increases AR and inflammation in the OVA/RSV model. METHODS: Wild-type (WT) BALB/c and IL-17A knockout (KO) mice underwent mock, RSV, OVA or OVA/RSV protocols. Lungs, bronchoalveolar lavage (BAL) fluid and/or mediastinal lymph nodes (MLNs) were harvested after infection. Cytokine expression was determined by ELISA in the lungs or BAL fluid. MLNs were restimulated with either OVA (323-229) peptide or RSV M2 (127-135) peptide and IL-17A protein expression was analysed. AR was determined by methacholine challenge. RESULTS:RSV increased IL-17A protein expression by OVA-specific T cells 6 days after infection. OVA/RSVmice had decreased interferon-β protein expression compared with RSVmice. OVA/RSVmice had increased IL-23p19 mRNA expression in lung homogenates compared with mock, OVA or RSVmice. Unexpectedly, IL-17A KO OVA/RSVmice had increased AR compared with WT OVA/RSVmice. Furthermore, IL-17A KO OVA/RSVmice had increased eosinophils, lymphocytes and IL-13 protein expression in BAL fluid compared with WT OVA/RSVmice. CONCLUSIONS:IL-17A negatively regulated AR and airway inflammation in OVA/RSVmice. This finding is important because IL-17A has been identified as a potential therapeutic target in asthma, and inhibiting IL-17A in the setting of virally-induced asthma exacerbations may have adverse consequences.
Authors: S Molet; Q Hamid; F Davoine; E Nutku; R Taha; N Pagé; R Olivenstein; J Elias; J Chakir Journal: J Allergy Clin Immunol Date: 2001-09 Impact factor: 10.793
Authors: Nele Sigurs; Per M Gustafsson; Ragnar Bjarnason; Fredrik Lundberg; Susanne Schmidt; Fridrik Sigurbergsson; Bengt Kjellman Journal: Am J Respir Crit Care Med Date: 2004-10-29 Impact factor: 21.405
Authors: Koichi Hashimoto; Barney S Graham; Samuel B Ho; Kenneth B Adler; Robert D Collins; Sandra J Olson; Weisong Zhou; Tatsuo Suzutani; Phillip W Jones; Kasia Goleniewska; Jamye F O'Neal; R Stokes Peebles Journal: Am J Respir Crit Care Med Date: 2004-05-06 Impact factor: 21.405
Authors: S L Johnston; P K Pattemore; G Sanderson; S Smith; F Lampe; L Josephs; P Symington; S O'Toole; S H Myint; D A Tyrrell Journal: BMJ Date: 1995-05-13
Authors: G Daniel Brooks; Kim A Buchta; Cheri A Swenson; James E Gern; William W Busse Journal: Am J Respir Crit Care Med Date: 2003-08-19 Impact factor: 21.405
Authors: Makoto Kudo; Andrew C Melton; Chun Chen; Mary B Engler; Katherine E Huang; Xin Ren; Yanli Wang; Xin Bernstein; John T Li; Kamran Atabai; Xiaozhu Huang; Dean Sheppard Journal: Nat Med Date: 2012-03-04 Impact factor: 53.440
Authors: Daniel Hsu; Patricia Taylor; Dave Fletcher; Rolf van Heeckeren; Jean Eastman; Anna van Heeckeren; Pamela Davis; James F Chmiel; Eric Pearlman; Tracey L Bonfield Journal: Infect Immun Date: 2016-08-19 Impact factor: 3.441
Authors: Sara L Hall; Theresa Baker; Stephane Lajoie; Phoebe K Richgels; Yanfen Yang; Jaclyn W McAlees; Adelaide van Lier; Marsha Wills-Karp; Umasundari Sivaprasad; Thomas H Acciani; Timothy D LeCras; Jocelyn Biagini Myers; Melinda Butsch Kovacic; Ian P Lewkowich Journal: J Allergy Clin Immunol Date: 2016-06-11 Impact factor: 10.793
Authors: Deepthi Kolli; Meera R Gupta; Elena Sbrana; Thangam S Velayutham; Hong Chao; Antonella Casola; Roberto P Garofalo Journal: Am J Respir Cell Mol Biol Date: 2014-10 Impact factor: 6.914
Authors: Kristi J Warren; Jill A Poole; Jenea M Sweeter; Jane M DeVasure; John D Dickinson; R Stokes Peebles; Todd A Wyatt Journal: Respir Res Date: 2021-07-15